Scilex Holding's Comment on Competition and Industry Peers
The company operates in the pain management market, competing with prescription, generic, and over-the-counter topical lidocaine patches. Competitors include Lidoderm and generic lidocaine patches produced by Teva, Mylan, and Par Pharmaceutical, Inc. The company cites its novel formulations, patents, and trade secrets as barriers to new entrants. It maintains supply agreements and manufacturing partnerships with Genzyme, an affiliate of Sanofi, and Tulex Pharmaceuticals Inc. The market is characterized by significant competition from pharmaceutical, biotechnology, and specialty pharmaceutical companies with established drug pipelines, capital resources, and research and development capabilities.
September 24, 2025
Scilex Holding Company (Nasdaq: SCLX), known for its focus on non-opioid pain management solutions, has been actively pursuing strategic partnerships and initiatives that signal its commitment to enhancing operational capabilities and market reach. Recently, the company announced a series of collaborations and agreements intended to bolster its product distribution and explore innovative financial strategies, including cryptocurrency.On September 24, 2025, Scilex entered a non-binding, non-exclusive Memorandum of Understanding (MOU) with Biconomy.com, a company specializing in cryptocurrency solutions. This MOU is aimed at developing future strategies concerning cryptocurrency management and treasury operati...
December 11, 2024
Innovative Pathways in Obesity Management: Scilex Bio Leads the Charge PALO ALTO, Calif. Dec. 11, 2024 In a groundbreaking step towards combatting obesity, Scilex Bio, a joint venture led by Scilex Holding Company (Nasdaq: SCLX), has announced the commencement of an ambitious Phase 2 clinical trial aimed at evaluating a novel therapeutic approach to this pressing health challenge. Notably, this trial will soon include a U.S. patient cohort set to enroll in 2025, marking a significant expansion in the trial s locale and potential impact.Scilex Bio, alongside its partner IPMC Company a pivotal player in the Bio Innovation Consortium, which maintains exclusive global rights to the promising new compound i...
July 17, 2024
Scilex Holding Company Collaborates with ACEA Therapeutics to Expand ZTlido Program in Greater China Region By PALO ALTO, Calif., July 17, 2024 Scilex Holding Company (Nasdaq: SCLX) a forward-looking, revenue-generating company committed to offering non-opioid pain management solutions has announced a strategic collaboration with ACEA Therapeutics, a China-based firm known for its innovative approaches to treating high unmet medical needs. This collaboration, firmly established through a Memorandum of Understanding (MOU), sets the stage for ACEA to potentially revolutionize the pain management landscape across several pivotal markets.Under the terms of the newly agreed MOU, ACEA Therapeutics could rec...
June 14, 2024
Scilex Holding Company Unveils Promising Phase 3 Trial Results and Strategic Advances in Pain Management and Gout Treatment Scilex Holding Company Accelerates Non-Opioid Therapeutic Innovations PALO ALTO, Calif., June 14, 2024 Scilex Holding Company (Nasdaq: SCLX), a forward-thinking, revenue-generating firm specializing in the acquisition, development, and commercialization of non-opioid pain management solutions for both acute and chronic pain, has recently announced significant developments across its product portfolio. These advances include critical Phase 3 results for its novel pain management drug SP-102 (SEMDEXA), the FDA approval for commercial manufacturing of Gloperba, and a landmark settleme...
June 13, 2024
PALO ALTO, Calif., June 13, 2024 Scilex Holding Company (Nasdaq: SCLX), renowned for its commitment to developing and commercializing non-opioid pain management products, is set to make significant strides in the treatment of acute and chronic pain. The company recently announced its participation in the 66th Annual Scientific Meeting of the American Headache Society (AHS), scheduled to take place in San Diego, CA, from June 13 to 16, 2024. During this prestigious event, Scilex will present a poster on ELYXYB® (celecoxib oral solution), a promising solution aimed at alleviating pain. ELYXYB®: A Pioneering Solution for Pain ManagementELYXYB® (celecoxib oral solution) represents a significant advancement...
May 13, 2024
In recent years, the practice of short selling has attracted significant attention due to its potential impact on the stability of the financial markets and individual companies. Scilex Holding Company, an innovative pharmaceutical firm focused on non-opioid pain management products, has recently addressed concerns about manipulative and naked short selling activity surrounding its common stock traded on the Nasdaq Capital Market. In this article, we will outline the facts surrounding these allegations and assess their potential impact on Scilex Holding Company.Background Information:Scilex Holding Company, listed as Nasdaq: SCLX, holds a strong market presence as a revenue-generating enterprise that special...
March 21, 2024
Scilex Holding Company, an innovative revenue-generating company specializing in non-opioid pain management products, has announced several significant developments. The company has capped out-of-pocket costs for commercially insured patients at $25 per month and as low as $0 for eligible patients. Furthermore, Scilex has obtained a Halal Certification for its postherpetic neuralgia pain product, ZTlido, indicating its compliance with Islamic standards. Additionally, Scilex has set the launch price of its novel liquid colchicine formulation, Gloperba, at $595 per 150ml bottle, providing precision dosing for gout patients.1. Capping out-of-pocket costs for commercially insured patients:Scilex is taking proact...
March 15, 2024
Scilex Holding Company, a renowned player in the non-opioid pain management sector, has recently achieved a significant milestone by obtaining the highly esteemed Halal Certification for its commercial product, ZTlido. This certification, granted by Circle H International, Inc., testifies that ZTlido meets the rigorous requirements set forth by Islamic standards. The team at Scilex is delighted with this accomplishment as it not only showcases the product s adherence to Islamic principles but also paves the way for the company s expansion into Islamic markets worldwide, particularly in the Middle East and North Africa (MENA) region.Facts and Impact:1. Scilex Holding s Revenue-Generating Focus:Scilex Holding ...
March 5, 2024
Scilex Holding Company Announces Launch of Gloperba, the First Liquid Colchicine for Painful Gout Flares, Priced at $595 per BottleIn an exciting development for gout sufferers, Scilex Holding Company has announced plans to launch Gloperba, the first liquid colchicine formulation for the prophylaxis of painful gout flares. Set to be available in the first half of 2024, Gloperba provides a much-needed alternative for patients with chronic kidney disease and gastrointestinal sensitivity, who require lower doses of colchicine than the standard tablet or capsule form.Gout is a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to severe pain, inflammation, and swelling. It is es...
February 28, 2024
Scilex Holding Company Partners with National Pharmacy Chain to Bring GLOPERBA to Wider Market PALO ALTO, Calif., Feb. 28, 2024 - Scilex Holding Company (Nasdaq: SCLX, Scilex or Company) has announced a groundbreaking partnership with a leading national pharmacy chain to make its innovative non-opioid pain management product, GLOPERBA, widely available in stores across the United States. This strategic collaboration aims to address the overwhelming demand for effective treatments for acute and chronic pain in the country.GLOPERBA, an FDA-approved prophylactic treatment for painful gout flares in adults, is anticipated to hit the U.S. market in the first half of 2024. The shared commitment of Scilex and the p...
Sources:
Scilex Holding Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scilex Holding Company versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
